Operating revenue elevated to GBP1.87 billion from GBP492 million within the fourth quarter of 2021, reflecting fair-value positive factors on investments, milestone revenue from disposals and decrease remeasurement costs for contingent consideration liabilities, GSK mentioned.

After-tax revenue additionally elevated, rising to GBP1.62 billion from GBP930 million the earlier yr.

Total earnings per share rose to 36.5 pence from 18.5 pence in 2021, and adjusted earnings per share elevated to 25.8 pence from 23.6 pence, GSK mentioned.

The firm reported a achieve from the demerger of its shopper healthcare enterprise–now named Haleon PLC–of GBP10.1 billion for the complete yr.

GSK’s vaccines enterprise was pushed each in 2022 and within the fourth quarter by gross sales of its shingles shot Shingrix, which generated GBP3 billion within the full yr and GBP769 million within the closing quarter. GSK’s specialty medicines division was pushed by progress in all therapeutic areas and totaled gross sales of GBP2.68 billion within the fourth quarter, the corporate mentioned.

For 2023, the corporate mentioned it expects turnover to extend between 6% and eight%, whereas adjusted working revenue is seen rising between 10% and 12%. Earnings per share are anticipated to rise between 12% and 15%, GSK mentioned. The steerage excludes any contribution from Covid-19 options, which aren’t anticipated to generate any important gross sales or working revenue within the present yr, GSK mentioned. Sales of Covid-19 options have been GBP2.4 billion in 2022. For 2023, the corporate expects a discount in turnover progress by about 9% and a discount in adjusted working revenue progress by 6% to 7%, it mentioned.

“Despite the recovery of healthcare systems, uncertain economic conditions prevail across many markets in which GSK operates and we continue to expect to see variability in performance between quarters,” the corporate mentioned.

Write to Cecilia Butini at cecilia.butini@wsj.com